Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond

Biological Psychiatry

Volumn 73, Issue 12, 2013, Pages 1133-1141

  Krystal, John H ^a,b,c   Sanacora, Gerard ^a,b   Duman, Ronald S ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Antidepressants glutamate ketamine rapid acting review treatment mechanisms

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; AZD 6765; CYCLOSERINE; GLUTAMIC ACID; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSION; HAMILTON SCALE; HUMAN; NEUROBIOLOGY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; GLUTAMIC ACID; HUMANS; KETAMINE;

EID: 84878409579     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.03.026     Document Type: Review

References (127)

1. F. Lopez-Munoz, and C. Alamo Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today Curr Pharm Des 15 2009 1563 1586
2. J. Donoghue Selective serotonin reuptake inhibitor use in primary care: A 5-year naturalistic study Clin Drug Investig 16 1998 453 462
3. E.H. Turner, A.M. Matthews, E. Linardatos, R.A. Tell, and R. Rosenthal Selective publication of antidepressant trials and its influence on apparent efficacy N Engl J Med 358 2008 252 260
4. I. Kirsch, B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore, and B.T. Johnson Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration PLoS Med 5 2008 e45
5. World Health Organization The Global Burden of Diseasse: 2004 Update 2008 WHO Press Geneva, Switzerland
6. B.N. Gaynes, D. Warden, M.H. Trivedi, S.R. Wisniewski, M. Fava, and A.J. Rush What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression Psychiatr Serv 60 2009 1439 1445
7. J.H. Krystal, G. S, H. Blumberg, A. Anand, D.S. Charney, and G. Marek Glutamate and GABA systems as targets for novel antidepressant and mood stabilizing treatments Mol Psychiatry 7 2002 S71 S80
8. G. Sanacora, C.A. Zarate, J.H. Krystal, and H.K. Manji Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nat Rev Drug Discov 7 2008 426 437
9. R.S. Duman, N. Li, R.J. Liu, V. Duric, and G. Aghajanian Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 2012 35 41
10. G.E. Crane Cycloserine as an antidepressant agent Am J Psychiatry 115 1959 1025 1026
11. G.E. Crane The psychotropic effect of cycloserine: A new use of an antibiotic Compr Psychiatry 2 1961 51 59
12. U. Heresco-Levy, G. Gelfin, B. Bloch, R. Levin, S. Edelman, and D.C. Javitt A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression Int J Neuropsychopharmacol 16 2013 501 506
13. A. Sheinin, S. Shavit, and M. Benveniste Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine Neuropharmacology 41 2001 151 158
14. S.M. Dravid, P.B. Burger, A. Prakash, M.T. Geballe, R. Yadav, and P. Le Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors J Neurosci 30 2010 2741 2754
15. S. Vale, M.A. Espejel, and J.C. Dominguez Amantadine in depression Lancet 2 1971 437
16. W. Danysz, C.G. Parsons, J. Kornhuber, W.J. Schmidt, and G. Quack Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies Neurosci Biobehav Rev 21 1997 455 468
17. C.A. Zarate Jr, J.B. Singh, J.A. Quiroz, G. De Jesus, K.K. Denicoff, and D.A. Luckenbaugh A double-blind, placebo-controlled study of memantine in the treatment of major depression Am J Psychiatry 163 2006 153 155
18. A. Anand, A.D. Gunn, G. Barkay, H.S. Karne, J.I. Nurnberger, and S.J. Mathew Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: A double-blind, randomized, placebo-controlled trial Bipolar Disord 14 2012 64 70
19. J. Stevens, R.R. Bies, A. Shekhar, and A. Anand Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression Br J Clin Pharmacol 75 2013 791 798
20. J.M. Ferguson, and R.N. Shingleton An open-label, flexible-dose study of memantine in major depressive disorder Clin Neuropharmacol 30 2007 136 144
21. C.A. Zarate Jr, D. Mathews, L. Ibrahim, J.F. Chaves, C. Marquardt, and I. Ukoh A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression [published online ahead of print November 30] Biol Psychiatry 2012
22. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol Sci 30 2009 563 569
23. R.D. Sofia, and J.J. Harakal Evaluation of ketamine HCl for anti-depressant activity Arch Int Pharmacodyn Ther 214 1975 68 74
24. R. Trullas, and P. Skolnick Functional antagonists at the NMDA receptor complex exhibit antidepressant actions Eur J Pharmacol 185 1990 1 10
25. R. Trullas, T. Folio, A. Young, R. Miller, K. Boje, and P. Skolnick 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models Eur J Pharmacol 203 1991 379 385
26. R.T. Layer, P. Popik, T. Olds, and P. Skolnick Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715) Pharmacol Biochem Behav 52 1995 621 627
27. G. Nowak, R. Trullas, R.T. Layer, P. Skolnick, and I.A. Paul Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid J Pharmacol Exp Ther 265 1993 1380 1386
28. I.A. Paul, R.T. Layer, P. Skolnick, and G. Nowak Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine Eur J Pharmacol 247 1993 305 311
29. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, and J.D. Bremner Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 1994 199 214
30. J.H. Krystal, D.C. D'Souza, D. Mathalon, E. Perry, A. Belger, and R. Hoffman NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development Psychopharmacology (Berl) 169 2003 215 233
31. J.H. Krystal, I.L. Petrakis, E. Krupitsky, C. Schutz, L. Trevisan, and D.C. D'Souza NMDA receptor antagonism and the ethanol intoxication signal: From alcoholism risk to pharmacotherapy Ann N Y Acad Sci 1003 2003 176 184
32. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
33. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
34. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, and S. Khalife A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch Gen Psychiatry 67 2010 793 802
35. L. Ibrahim, N. Diazgranados, D.A. Luckenbaugh, R. Machado-Vieira, J. Baumann, and A.G. Mallinger Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1155 1159
36. M. Aan Het Rot, C.A. Zarate Jr, D.S. Charney, and S.J. Mathew Ketamine for depression: Where do we go from here? Biol Psychiatry 72 2012 537 547
37. J.W. Murrough Ketamine as a novel antidepressant: From synapse to behavior Clin Pharmacol Ther 91 2012 303 309
38. N. Diazgranados, L.A. Ibrahim, N.E. Brutsche, R. Ameli, I.D. Henter, and D.A. Luckenbaugh Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder J Clin Psychiatry 71 2010 1605 1611
39. R.B. Price, M.K. Nock, D.S. Charney, and S.J. Mathew Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression Biol Psychiatry 66 2009 522 526
40. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, and S. Khalife A randomized add-on trial of an N-methyl-D-aspartate (NMDA) antagonist in treatment-resistant bipolar depression Arch Gen Psychiatry 67 2010 793 802
41. L.E. Phelps, N. Brutsche, J.R. Moral, D.A. Luckenbaugh, H.K. Manji, and C.A. Zarate Jr Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist Biol Psychiatry 65 2009 181 184
42. D.A. Luckenbaugh, L. Ibrahim, N. Brutsche, J. Franco-Chaves, D. Mathews, and C.A. Marquardt Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression Bipolar Disord 14 2012 880 887
43. L.H. Muhonen, J. Lonnqvist, K. Juva, and H. Alho Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence J Clin Psychiatry 69 2008 392 399
44. D. Thangathurai, J. Roby, and P. Roffey Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine J Palliat Med 13 2010 235
45. C.G. Zanicotti, D. Perez, and P. Glue Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer J Palliat Med 15 2012 400 403
46. D.L. Reich, and G. Silvay Ketamine: An update on the first twenty-five years of clinical experience Can J Anaesthesiol 36 1989 186 197
47. E.B. Perry Jr, J.A. Cramer, H.S. Cho, I.L. Petrakis, L.P. Karper, and A. Genovese Psychiatric safety of ketamine in psychopharmacology research Psychopharmacology (Berl) 192 2007 253 260
48. W.T. Carpenter Jr. The schizophrenia ketamine challenge study debate Biol Psychiatry 46 1999 1081 1091
49. A.C. Lahti, D. Warfel, T. Michaelidis, M.A. Weiler, K. Frey, and C.A. Tamminga Long-term outcome of patients who receive ketamine during research Biol Psychiatry 49 2001 869 875
50. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, and D.S. Charney Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol Psychiatry 67 2010 139 145
51. C.A. Zarate Jr, N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, and A. Cravchik Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial Biol Psychiatry 71 2012 939 946
52. C. Cusin, G.Q. Hilton, A.A. Nierenberg, and M. Fava Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression Am J Psychiatry 169 2011 868 869
53. A.K. Ricke, R.J. Snook, and A. Anand Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy Biol Psychiatry 70 2011 e13 14
54. E.B. Perry, J. Cramer, H.-S. Cho, I. Petrakis, L. Karper, and J.H. Krystal Psychiatric safety of ketamine in clinical psychopharmacology research Psychopharmacology 192 2007 253 260
55. S.H. Ng, M.L. Tse, H.W. Ng, and F.L. Lau Emergency department presentation of ketamine abusers in Hong Kong: A review of 233 cases Hong Kong Med J 16 2010 6 11
56. S.A. Irwin, and A. Iglewicz Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care J Palliat Med 13 2010 903 908
57. G. Paslakis, M. Gilles, A. Meyer-Lindenberg, and M. Deuschle Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: A case series Pharmacopsychiatry 43 2010 33 35
58. M.D. Wilson, R.W. Ferguson, M.E. Mazer, and T.L. Litovitz Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000-2010 Clin Toxicol (Phila) 49 2011 409 415
59. C.J. Reissig, L.P. Carter, M.W. Johnson, M.Z. Mintzer, M.A. Klinedinst, and R.R. Griffiths High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens Psychopharmacology (Berl) 223 2011 1 15
60. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan Het Rot M, et al. (2012): Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression [published online ahead of print July 26]. Biol Psychiatry.
61. K.A. Trujillo, J.J. Zamora, and K.P. Warmoth Increased response to ketamine following treatment at long intervals: Implications for intermittent use Biol Psychiatry 63 2008 178 183
62. H.S. Cho, D.C. D'Souza, R. Gueorguieva, E.B. Perry, S. Madonick, and L.P. Karper Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine Psychopharmacology (Berl) 179 2005 136 143
63. P. Blier, D. Zigman, and J. Blier On the safety and benefits of repeated intravenous injections of ketamine for depression Biol Psychiatry 72 2012 e11 e12
64. J.W. Murrough, A.M. Perez, S.J. Mathew, and D.S. Charney A case of sustained remission following an acute course of ketamine in treatment-resistant depression J Clin Psychiatry 72 2011 414 415
65. D.T. Manallack, D. Lodge, and P.M. Beart Subchronic administration of MK-801 in the rat decreases cortical binding of [3H]D-AP5, suggesting down-regulation of the cortical N-methyl-D-aspartate receptors Neuroscience 30 1989 87 94
66. I. Braun, J. Genius, H. Grunze, A. Bender, H.J. Moller, and D. Rujescu Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism Schizophr Res 97 2007 254 263
67. J.D. Jentsch, J.R. Taylor, and R.H. Roth Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion Neuropsychopharmacology 19 1998 105 113
68. J.D. Jentsch, D.E. Redmond Jr, J.D. Elsworth, J.R. Taylor, K.D. Youngren, and R.H. Roth Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine Science 277 1997 953 955
69. J.C. Neill, S. Barnes, S. Cook, B. Grayson, N.F. Idris, and S.L. McLean Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism Pharmacol Ther 128 2010 419 432
70. M.M. Behrens, and T.J. Sejnowski Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology 57 2009 193 200
71. F.R. Sharp, M. Butman, J. Koistinaho, K. Aardalen, R. Nakki, and S.M. Massa Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels Neuroscience 62 1994 1079 1092
72. J.W. Olney, J. Labruyere, and M.T. Price Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs Science 244 1989 1360 1362
73. R. Nakki, J. Nickolenko, J. Chang, S.M. Sagar, and F.R. Sharp Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation Exp Neurol 137 1996 234 241
74. C.J. Morgan, and H.V. Curran Acute and chronic effects of ketamine upon human memory: A review Psychopharmacology (Berl) 188 2006 408 424
75. C.J. Morgan, and H.V. Curran Ketamine use: A review Addiction 107 2012 27 38
76. Y. Liao, J. Tang, M. Ma, Z. Wu, M. Yang, and X. Wang Frontal white matter abnormalities following chronic ketamine use: A diffusion tensor imaging study Brain 133 2010 2115 2122
77. Y. Liao, J. Tang, P.R. Corlett, X. Wang, M. Yang, and H. Chen Reduced dorsal prefrontal gray matter after chronic ketamine use Biol Psychiatry 69 2011 42 48
78. Y. Liao, J. Tang, A. Fornito, T. Liu, X. Chen, and H. Chen Alterations in regional homogeneity of resting-state brain activity in ketamine addicts Neurosci Lett 522 2012 36 40
79. L.Y. Chen, K.P. Chen, and M.C. Huang Cystitis associated with chronic ketamine abuse Psychiatry Clin Neurosci 63 2009 591
80. S.W. Wong, K.F. Lee, J. Wong, W.W. Ng, Y.S. Cheung, and P.B. Lai Dilated common bile ducts mimicking choledochal cysts in ketamine abusers Hong Kong Med J 15 2009 53 56
81. S.J. Mathew, J.W. Murrough, M. aan het Rot, K.A. Collins, D.L. Reich, and D.S. Charney Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial Int J Neuropsychopharmacol 13 2010 71 82
82. L. Ibrahim, N. Diazgranados, J. Franco-Chaves, N. Brutsche, I.D. Henter, and P. Kronstein Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study Neuropsychopharmacology 37 2012 1526-1433
83. J.R. Geddes, G.M. Goodwin, J. Rendell, J.M. Azorin, A. Cipriani, and M.J. Ostacher Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial Lancet 375 2010 385 395
84. C. Baethge, P. Gruschka, M.N. Smolka, A. Berghofer, T. Bschor, and B. Muller-Oerlinghausen Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder J Psychiatry Neurosci 28 2003 355 361
85. R.F. Prien, D.J. Kupfer, P.A. Mansky, J.G. Small, V.B. Tuason, and C.B. Voss Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination Arch Gen Psychiatry 41 1984 1096 1104
86. C. Spanier, E. Frank, A.B. McEachran, V.J. Grochocinski, and D.J. Kupfer The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: Integrating psychological and biological factors Psychol Med 26 1996 461 475
87. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
88. J.H. Krystal, D.F. Tolin, G. Sanacora, S.A. Castner, G.V. Williams, and D.E. Aikins Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia Drug Discov Today 14 2009 690 697
89. E. Beurel, L. Song, and R.S. Jope Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice Mol Psychiatry 16 2011 1068 1070
90. H.K. Manji, G.J. Moore, and G. Chen Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46 1999 929 940
91. J.H. Krystal, G. Sanacora, H. Blumberg, A. Anand, D.S. Charney, and G. Marek Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments Mol Psychiatry 7 suppl 1 2007 S71 S80
92. P.E. Holtzheimer, and H.S. Mayberg Stuck in a rut: Rethinking depression and its treatment Trends Neurosci 34 2011 1 9
93. P.J. Magistretti, L. Pellerin, D.L. Rothman, and R.G. Shulman Energy on demand Science 283 1999 496 497
94. G. Rajkowska, and J.J. Miguel-Hidalgo Gliogenesis and glial pathology in depression CNS Neurol Disord Drug Targets 6 2007 219 233
95. G. Rajkowska Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells Biol Psychiatry 48 2000 766 777
96. M. Banasr, J.M. Dwyer, and R.S. Duman Cell atrophy and loss in depression: Reversal by antidepressant treatment Curr Opin Cell Biol 23 2011 730 737
97. R.S. Duman, and B. Voleti Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents Trends Neurosci 35 2012 47 56
98. M. Banasr, G.M. Chowdhury, R. Terwilliger, S.S. Newton, R.S. Duman, and K.L. Behar Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole Mol Psychiatry 15 2008 501 511
99. C. Bonansco, A. Couve, G. Perea, C.A. Ferradas, M. Roncagliolo, and M. Fuenzalida Glutamate released spontaneously from astrocytes sets the threshold for synaptic plasticity Eur J Neurosci 33 2011 1483 1492
100. D.I. Horn, C. Yu, J. Steiner, J. Buchmann, J. Kaufmann, and A. Osoba Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula Front Syst Neurosci 15 2010 4
101. F. Chaouloff, A. Hemar, and O. Manzoni Acute stress facilitates hippocampal CA1 metabotropic glutamate receptor-dependent long-term depression J Neurosci 27 2007 7130 7135
102. G.E. Hardingham, and H. Bading Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders Nat Rev Neurosci 11 2010 682 696
103. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
104. H.J. Kang, B. Voleti, T. Hajszan, G. Rajkowska, C.A. Stockmeier, and P. Licznerski Decreased expression of synapse-related genes and loss of synapses in major depressive disorder Nat Med 18 2012 1413 1417
105. B. Kronenberger, T. Berg, E. Herrmann, H. Hinrichsen, T. Gerlach, and P. Buggisch Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial Eur J Gastroenterol Hepatol 19 2007 639 646
106. L.B. Krupp, P.K. Coyle, C. Doscher, A. Miller, A.H. Cross, and L. Jandorf Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo Neurology 45 1995 1956 1961
107. M. Kubera, M. Maes, B. Budziszewska, A. Basta-Kaim, M. Leskiewicz, and B. Grygier Inhibitory effects of amantadine on the production of pro-inflammatory cytokines by stimulated in vitro human blood Pharmacol Rep 61 2009 1105 1112
108. J.M. Stone, C. Dietrich, R. Edden, M.A. Mehta, S. De Simoni, and L.J. Reed Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology Mol Psychiatry 17 2012 664 665
109. G.M. Chowdhury, K.L. Behar, W. Cho, M.A. Thomas, D.L. Rothman, and G. Sanacora (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism Biol Psychiatry 71 2012 1022 1025
110. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 17 1997 2921 2927
111. S. Maeng, C.A. Zarate Jr, J. Du, R.J. Schloesser, J. McCammon, and G. Chen Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 2008 349 352
112. G. Salvadore, J.W. van der Veen, Y. Zhang, S. Marenco, R. Machado-Vieira, and J. Baumann An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression Int J Neuropsychopharmacol 15 2012 1063 1072
113. R.J. Liu, F.S. Lee, X.Y. Li, F. Bambico, R.S. Duman, and G.K. Aghajanian Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex Biol Psychiatry 71 2012 996 1005
114. G. Laje, N. Lally, D. Mathews, N. Brutsche, A. Chemerinski, and N. Akula Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients Biol Psychiatry 72 2012 e27 28
115. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J Clin Psychopharmacol 28 2008 631 637
116. L. Ibrahim, N. Diazgranados, L. Jolkovsky, N. Brutsche, D.A. Luckenbaugh, and W.J. Herring A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder J Clin Psychopharmacol 32 2012 551 557
117. J. Burgdorf, R.A. Kroes, C. Weiss, M.M. Oh, J.F. Disterhoft, and S.M. Brudzynski Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors Neuroscience 192 2011 515 523
118. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, and N. Kawashima MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467
119. J.M. Dwyer, A.E. Lepack, and R.S. Duman mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade Int J Neuropsychopharmacol 15 2012 429 434
120. J.H. Krystal, S.J. Mathew, D.C. D'Souza, A. Garakani, H. Gunduz-Bruce, and D.S. Charney Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists CNS Drugs 24 2010 669 693
121. A. Palucha, P. Branski, B. Szewczyk, J.M. Wieronska, K. Klak, and A. Pilc Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist Pharmacol Biochem Behav 81 2005 901 906
122. I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, and A.Y. Bespalov Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur Neuropsychopharmacol 17 2007 172 179
123. R.J. Knapp, R. Goldenberg, C. Shuck, A. Cecil, J. Watkins, and C. Miller Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model Eur J Pharmacol 440 2002 27 35
124. P. Gallagher, N. Malik, J. Newham, A.H. Young, I.N. Ferrier, and P. Mackin Antiglucocorticoid treatments for mood disorders Cochrane Database Syst Rev 1 2008 CD005168
125. C.L. Raison, R.E. Rutherford, B.J. Woolwine, C. Shuo, P. Schettler, and D.F. Drake A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers JAMA Psychiatry 70 2012 31 41
126. M. Berk, D.L. Copolov, O. Dean, K. Lu, S. Jeavons, and I. Schapkaitz N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial Biol Psychiatry 64 2008 468 475
127. G. Sanacora, S.F. Kendell, L. Fenton, V. Coric, and J.H. Krystal Riluzole augmentation for treatment-resistant depression Am J Psychiatry 161 2004 2132